Wire · opportunities
Pharvaris ph. 3 win builds case for HAE drug sitting with FDA
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 September 2026 · Fusion42 review
Pharvaris achieved positive phase 3 trial results for deucrictibant, an oral therapy for hereditary angioedema (HAE), strengthening its case for FDA approval anticipated in April 2027. The treatment showed significant reduction in HAE attacks and performed well across secondary endpoints.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Pharvaris' FDA approval bid for an oral HAE drug creates a market opening where injectable options have dominated. You should now evaluate opportunities to serve patients seeking non-injectable treatments or complement existing HAE therapies.
◆ Coverage
1 source · 8 Sep 2026
◆ Related on Wire
◆ Topics